When testosterone was synthesized in 1935, the pharmaceutical industry had a choice.
It could focus on perfecting testosterone replacement — developing delivery methods that gave hypogonadal men stable, physiological levels of the hormone they were missing. It could build the clinical evidence base. It could design better formulations.
Or it could go looking for variants.
The industry went looking for variants. For several decades, research on testosterone itself was largely abandoned in favor of the search for better molecules — synthetic androgens that could be patented, differentiated, and sold as improvements. Some of those molecules turned out to be useful. Many of them turned out to be problems. And the patients who simply needed testosterone replacement waited decades for formulations that could actually deliver what they needed.
The Syndrome Descriptions Arrive (Right on Time)
It was not coincidental that the major clinical syndromes of testosterone deficiency were first formally described at almost exactly the same time that testosterone became clinically available.
In 1942, Harry Klinefelter described a syndrome now bearing his name: the most common form of primary male hypogonadism, caused by an extra X chromosome (XXY), resulting in small testes, infertility, and insufficient testosterone production. The syndrome had presumably existed for all of human history, but there was no treatment to offer before 1935. Once there was, physicians looked harder.
In 1944, Franz Josef Kallmann described hypogonadotropic hypogonadism — hypogonadism caused not by a problem with the testes themselves but by a failure of the brain signals that tell the testes to produce testosterone. Again: the syndrome became clinically interesting once there was something to do about it.
The 1950s brought further descriptions: Pasqualini and Bur described the fertile-eunuch syndrome in 1950. Del Castillo described Sertoli-cell-only syndrome in 1947. The clinical picture of testosterone deficiency was finally being mapped, systematically, by physicians who could now imagine treating it.
The Injection Era
For the first three to four decades after 1935, testosterone replacement meant injections.
Testosterone propionate — a short-acting ester — required injections every two to three days. This was demanding for patients and became the standard of care only because there was no alternative. By the mid-1950s, testosterone enanthate offered a longer-acting option: injections every two to four weeks.
Testosterone enanthate became the dominant form of testosterone therapy for nearly half a century. It was effective at raising testosterone levels. It was relatively inexpensive. It was familiar to physicians who had been using it for years.
It was also pharmacologically crude.
At 36 to 48 hours after injection, serum testosterone levels were supraphysiological — significantly above normal. By days 7 through 14, levels were in the physiological range. By days 21 through 28, as the next injection approached, levels fell into the subtherapeutic range — sometimes below the clinical threshold for hypogonadism.
Men on the standard injection protocol spent a significant portion of each cycle feeling the effects of hormone excess or deficiency. The goal of therapy — maintaining physiological testosterone levels — was barely achievable with two-weekly injections. The pharmacokinetics simply didn’t support it.
Clinicians assembled at a WHO, NIH, and FDA workshop on androgen therapy in 1990 were blunt about this: the consensus view was that the major goal of therapy should be to replace testosterone levels as close to physiologic concentrations as possible, and that none of the available preparations did this reliably.
The Anabolic Steroid Detour
While patients who genuinely needed testosterone waited for better delivery, the pharmaceutical industry was busy creating variants.
The logic was sound in theory: testosterone does many things — it builds muscle, maintains bone density, governs libido, affects mood and cognition, regulates red blood cell production, and mediates sexual development. If you could modify the molecule to emphasize muscle-building (anabolic) effects while reducing masculinizing (androgenic) effects, you could have a compound with broad clinical use.
By 1956, pharmaceutical textbooks already described 256 distinct androgenic steroids. By 1976, the number exceeded a thousand.
The “pure anabolic” was never found. Every modification that increased anabolic potency retained androgenic activity — the two properties couldn’t be fully separated because they both derived from the same receptor interaction. What the industry did find was a long list of compounds with varying ratios of anabolic to androgenic activity, variable hepatotoxicity, and unpredictable side effect profiles.
Most of these compounds eventually disappeared from clinical medicine. They didn’t disappear from sports. The same molecular diversity that failed to produce a better therapeutic agent produced an enormous toolkit for athletic doping — compounds that evaded testing, circulated on black markets, and caused documented harm in athletes who used them at supraphysiological doses for years.
Testosterone Undecanoate: The First Oral Salvage
In the late 1970s, a form of testosterone that could be taken orally without liver toxicity finally became available: testosterone undecanoate.
The trick was in the ester. By attaching an undecanoate chain to the testosterone molecule, chemists created a form that was absorbed from the gut not directly into the portal blood (where it would go straight to the liver) but into the lymphatic system — bypassing the liver and achieving meaningful blood levels.
The bioavailability was low and variable. The patient needed to take it with a fatty meal for the lymphatic absorption to work effectively. The dosing was inconvenient. But it was oral testosterone that wasn’t liver toxic, and it became clinically useful for patients who couldn’t or wouldn’t use injections.
The Moment the Field Realized What It Had Missed
By 1990, the field’s self-assessment was frank. The 1990 WHO/NIH/FDA workshop’s conclusion — that the goal of physiological testosterone replacement was not being achieved by available preparations — was an admission that fifty years of pharmaceutical development had not produced what patients actually needed.
The problem was pharmacokinetics, not pharmacology. Testosterone itself was fine. The ways it was being delivered — in ester form via injection, or in oral forms with variable bioavailability — created serum level profiles that swung between excess and deficiency rather than approximating what a healthy testis would produce.
The solution was transdermal delivery. The skin could absorb testosterone continuously, mimicking the natural daily production pattern, avoiding first-pass liver metabolism, and providing stable rather than roller-coaster serum levels.
That realization drove the next generation of development.
What’s Next — Series 3
Next, we follow the molecule into the clinic — and into millions of syringes. Series 3 examines testosterone’s injection era: why the first forms required injections every three days, why enanthate became the gold standard, and why millions of men eventually walked away from needles altogether.
